nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitagliptin—ABCB1—Mitomycin—urinary bladder cancer	0.196	0.302	CbGbCtD
Sitagliptin—CYP3A4—Thiotepa—urinary bladder cancer	0.089	0.137	CbGbCtD
Sitagliptin—CYP2C8—Fluorouracil—urinary bladder cancer	0.0713	0.11	CbGbCtD
Sitagliptin—CYP2C8—Etoposide—urinary bladder cancer	0.0595	0.0918	CbGbCtD
Sitagliptin—ABCB1—Gemcitabine—urinary bladder cancer	0.0564	0.087	CbGbCtD
Sitagliptin—ABCB1—Cisplatin—urinary bladder cancer	0.041	0.0632	CbGbCtD
Sitagliptin—ABCB1—Etoposide—urinary bladder cancer	0.0403	0.0621	CbGbCtD
Sitagliptin—ABCB1—Doxorubicin—urinary bladder cancer	0.0275	0.0424	CbGbCtD
Sitagliptin—ABCB1—Methotrexate—urinary bladder cancer	0.0266	0.0411	CbGbCtD
Sitagliptin—CYP3A4—Etoposide—urinary bladder cancer	0.0241	0.0372	CbGbCtD
Sitagliptin—CYP3A4—Doxorubicin—urinary bladder cancer	0.0165	0.0254	CbGbCtD
Sitagliptin—DPP4—Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)—CDX2—urinary bladder cancer	0.00897	0.149	CbGpPWpGaD
Sitagliptin—DPP4—Incretin synthesis, secretion, and inactivation—CDX2—urinary bladder cancer	0.00798	0.132	CbGpPWpGaD
Sitagliptin—DPP4—prostate gland—urinary bladder cancer	0.00503	0.115	CbGeAlD
Sitagliptin—CYP3A4—urine—urinary bladder cancer	0.00457	0.105	CbGeAlD
Sitagliptin—DPP4—seminal vesicle—urinary bladder cancer	0.00425	0.0973	CbGeAlD
Sitagliptin—ABCB1—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00394	0.0653	CbGpPWpGaD
Sitagliptin—DPP4—epithelium—urinary bladder cancer	0.0037	0.0846	CbGeAlD
Sitagliptin—DPP4—smooth muscle tissue—urinary bladder cancer	0.00356	0.0815	CbGeAlD
Sitagliptin—DPP4—renal system—urinary bladder cancer	0.00343	0.0784	CbGeAlD
Sitagliptin—DPP4—female reproductive system—urinary bladder cancer	0.00275	0.0628	CbGeAlD
Sitagliptin—DPP4—Peptide hormone metabolism—CDX2—urinary bladder cancer	0.00271	0.0449	CbGpPWpGaD
Sitagliptin—DPP4—vagina—urinary bladder cancer	0.00248	0.0568	CbGeAlD
Sitagliptin—CYP3A4—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00243	0.0402	CbGpPWpGaD
Sitagliptin—CYP2C8—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00209	0.0346	CbGpPWpGaD
Sitagliptin—CYP2C8—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00169	0.0281	CbGpPWpGaD
Sitagliptin—CYP2C8—renal system—urinary bladder cancer	0.00165	0.0378	CbGeAlD
Sitagliptin—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—urinary bladder cancer	0.00162	0.0269	CbGpPWpGaD
Sitagliptin—DPP4—lymph node—urinary bladder cancer	0.00161	0.0368	CbGeAlD
Sitagliptin—CYP2C8—female reproductive system—urinary bladder cancer	0.00132	0.0302	CbGeAlD
Sitagliptin—CYP3A4—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.00127	0.021	CbGpPWpGaD
Sitagliptin—CYP2C8—vagina—urinary bladder cancer	0.0012	0.0274	CbGeAlD
Sitagliptin—ABCB1—prostate gland—urinary bladder cancer	0.00116	0.0266	CbGeAlD
Sitagliptin—CYP3A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00112	0.0186	CbGpPWpGaD
Sitagliptin—CYP3A4—renal system—urinary bladder cancer	0.00112	0.0256	CbGeAlD
Sitagliptin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00111	0.0185	CbGpPWpGaD
Sitagliptin—ABCB1—seminal vesicle—urinary bladder cancer	0.000982	0.0225	CbGeAlD
Sitagliptin—CYP2C8—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.00094	0.0156	CbGpPWpGaD
Sitagliptin—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.000909	0.0151	CbGpPWpGaD
Sitagliptin—CYP3A4—female reproductive system—urinary bladder cancer	0.000895	0.0205	CbGeAlD
Sitagliptin—ABCB1—epithelium—urinary bladder cancer	0.000853	0.0195	CbGeAlD
Sitagliptin—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000812	0.0135	CbGpPWpGaD
Sitagliptin—CYP2C8—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000801	0.0133	CbGpPWpGaD
Sitagliptin—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.000799	0.0132	CbGpPWpGaD
Sitagliptin—ABCB1—renal system—urinary bladder cancer	0.000791	0.0181	CbGeAlD
Sitagliptin—ABCB1—urethra—urinary bladder cancer	0.000777	0.0178	CbGeAlD
Sitagliptin—DPP4—Peptide hormone metabolism—IGF1—urinary bladder cancer	0.000718	0.0119	CbGpPWpGaD
Sitagliptin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000687	0.0114	CbGpPWpGaD
Sitagliptin—CYP2C8—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000658	0.0109	CbGpPWpGaD
Sitagliptin—ABCB1—female reproductive system—urinary bladder cancer	0.000634	0.0145	CbGeAlD
Sitagliptin—ABCB1—vagina—urinary bladder cancer	0.000573	0.0131	CbGeAlD
Sitagliptin—ABCB1—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000571	0.00947	CbGpPWpGaD
Sitagliptin—DPP4—Metabolism of proteins—CDX2—urinary bladder cancer	0.000511	0.00848	CbGpPWpGaD
Sitagliptin—CYP2C8—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.0005	0.00829	CbGpPWpGaD
Sitagliptin—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.00049	0.00812	CbGpPWpGaD
Sitagliptin—CYP2C8—Biological oxidations—GSTZ1—urinary bladder cancer	0.000448	0.00743	CbGpPWpGaD
Sitagliptin—CYP2C8—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000442	0.00733	CbGpPWpGaD
Sitagliptin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000436	0.00723	CbGpPWpGaD
Sitagliptin—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00043	0.00713	CbGpPWpGaD
Sitagliptin—CYP2C8—Biological oxidations—GSTO2—urinary bladder cancer	0.000425	0.00704	CbGpPWpGaD
Sitagliptin—CYP2C8—Biological oxidations—NAT1—urinary bladder cancer	0.000425	0.00704	CbGpPWpGaD
Sitagliptin—CYP2C8—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000419	0.00695	CbGpPWpGaD
Sitagliptin—CYP2C8—Biological oxidations—UGT2B7—urinary bladder cancer	0.000388	0.00644	CbGpPWpGaD
Sitagliptin—CYP2C8—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000383	0.00635	CbGpPWpGaD
Sitagliptin—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000375	0.00622	CbGpPWpGaD
Sitagliptin—ABCB1—lymph node—urinary bladder cancer	0.000371	0.00848	CbGeAlD
Sitagliptin—Diarrhoea—Thiotepa—urinary bladder cancer	0.000356	0.00144	CcSEcCtD
Sitagliptin—Decreased appetite—Cisplatin—urinary bladder cancer	0.000355	0.00143	CcSEcCtD
Sitagliptin—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000355	0.00143	CcSEcCtD
Sitagliptin—Bronchitis—Epirubicin—urinary bladder cancer	0.000355	0.00143	CcSEcCtD
Sitagliptin—Pneumonia—Methotrexate—urinary bladder cancer	0.000353	0.00143	CcSEcCtD
Sitagliptin—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000353	0.00586	CbGpPWpGaD
Sitagliptin—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000353	0.00142	CcSEcCtD
Sitagliptin—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000353	0.00142	CcSEcCtD
Sitagliptin—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000352	0.00584	CbGpPWpGaD
Sitagliptin—Infestation NOS—Methotrexate—urinary bladder cancer	0.000351	0.00142	CcSEcCtD
Sitagliptin—Infestation—Methotrexate—urinary bladder cancer	0.000351	0.00142	CcSEcCtD
Sitagliptin—Depression—Methotrexate—urinary bladder cancer	0.00035	0.00141	CcSEcCtD
Sitagliptin—CYP2C8—Biological oxidations—CYP4B1—urinary bladder cancer	0.00035	0.0058	CbGpPWpGaD
Sitagliptin—Pain—Cisplatin—urinary bladder cancer	0.000349	0.00141	CcSEcCtD
Sitagliptin—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000348	0.0014	CcSEcCtD
Sitagliptin—Renal failure—Methotrexate—urinary bladder cancer	0.000345	0.00139	CcSEcCtD
Sitagliptin—CYP2C8—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000345	0.00572	CbGpPWpGaD
Sitagliptin—Dizziness—Thiotepa—urinary bladder cancer	0.000344	0.00139	CcSEcCtD
Sitagliptin—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000343	0.00138	CcSEcCtD
Sitagliptin—Urticaria—Fluorouracil—urinary bladder cancer	0.000342	0.00138	CcSEcCtD
Sitagliptin—Influenza—Doxorubicin—urinary bladder cancer	0.000341	0.00138	CcSEcCtD
Sitagliptin—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000337	0.00136	CcSEcCtD
Sitagliptin—Weight increased—Epirubicin—urinary bladder cancer	0.000336	0.00135	CcSEcCtD
Sitagliptin—Pancreatitis—Doxorubicin—urinary bladder cancer	0.000335	0.00135	CcSEcCtD
Sitagliptin—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000333	0.00134	CcSEcCtD
Sitagliptin—Somnolence—Etoposide—urinary bladder cancer	0.000333	0.00134	CcSEcCtD
Sitagliptin—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000332	0.00134	CcSEcCtD
Sitagliptin—Vomiting—Thiotepa—urinary bladder cancer	0.000331	0.00134	CcSEcCtD
Sitagliptin—Pneumonia—Epirubicin—urinary bladder cancer	0.000331	0.00133	CcSEcCtD
Sitagliptin—Infestation—Epirubicin—urinary bladder cancer	0.000329	0.00133	CcSEcCtD
Sitagliptin—Infestation NOS—Epirubicin—urinary bladder cancer	0.000329	0.00133	CcSEcCtD
Sitagliptin—Rash—Thiotepa—urinary bladder cancer	0.000328	0.00132	CcSEcCtD
Sitagliptin—Bronchitis—Doxorubicin—urinary bladder cancer	0.000328	0.00132	CcSEcCtD
Sitagliptin—Dermatitis—Thiotepa—urinary bladder cancer	0.000328	0.00132	CcSEcCtD
Sitagliptin—Headache—Thiotepa—urinary bladder cancer	0.000326	0.00132	CcSEcCtD
Sitagliptin—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000326	0.00131	CcSEcCtD
Sitagliptin—Decreased appetite—Etoposide—urinary bladder cancer	0.000325	0.00131	CcSEcCtD
Sitagliptin—Renal failure—Epirubicin—urinary bladder cancer	0.000323	0.0013	CcSEcCtD
Sitagliptin—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000323	0.0013	CcSEcCtD
Sitagliptin—Fatigue—Etoposide—urinary bladder cancer	0.000323	0.0013	CcSEcCtD
Sitagliptin—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000322	0.0013	CcSEcCtD
Sitagliptin—DPP4—Metabolism of proteins—IGFBP3—urinary bladder cancer	0.000321	0.00532	CbGpPWpGaD
Sitagliptin—Constipation—Etoposide—urinary bladder cancer	0.00032	0.00129	CcSEcCtD
Sitagliptin—Pain—Etoposide—urinary bladder cancer	0.00032	0.00129	CcSEcCtD
Sitagliptin—Urinary tract infection—Epirubicin—urinary bladder cancer	0.00032	0.00129	CcSEcCtD
Sitagliptin—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000317	0.00128	CcSEcCtD
Sitagliptin—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000317	0.00128	CcSEcCtD
Sitagliptin—ABCB1—HIF-1-alpha transcription factor network—TFRC—urinary bladder cancer	0.000317	0.00526	CbGpPWpGaD
Sitagliptin—Asthenia—Gemcitabine—urinary bladder cancer	0.000314	0.00127	CcSEcCtD
Sitagliptin—Pharyngitis—Methotrexate—urinary bladder cancer	0.000313	0.00126	CcSEcCtD
Sitagliptin—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000312	0.00126	CcSEcCtD
Sitagliptin—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000311	0.00125	CcSEcCtD
Sitagliptin—Weight increased—Doxorubicin—urinary bladder cancer	0.000311	0.00125	CcSEcCtD
Sitagliptin—Nausea—Thiotepa—urinary bladder cancer	0.000309	0.00125	CcSEcCtD
Sitagliptin—Urethral disorder—Methotrexate—urinary bladder cancer	0.000309	0.00125	CcSEcCtD
Sitagliptin—Sinusitis—Epirubicin—urinary bladder cancer	0.000309	0.00124	CcSEcCtD
Sitagliptin—Feeling abnormal—Etoposide—urinary bladder cancer	0.000308	0.00124	CcSEcCtD
Sitagliptin—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000308	0.00124	CcSEcCtD
Sitagliptin—Pneumonia—Doxorubicin—urinary bladder cancer	0.000306	0.00123	CcSEcCtD
Sitagliptin—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000306	0.00123	CcSEcCtD
Sitagliptin—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000304	0.00123	CcSEcCtD
Sitagliptin—Infestation—Doxorubicin—urinary bladder cancer	0.000304	0.00123	CcSEcCtD
Sitagliptin—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000302	0.00122	CcSEcCtD
Sitagliptin—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000301	0.00121	CcSEcCtD
Sitagliptin—Diarrhoea—Gemcitabine—urinary bladder cancer	0.0003	0.00121	CcSEcCtD
Sitagliptin—Renal failure—Doxorubicin—urinary bladder cancer	0.000299	0.00121	CcSEcCtD
Sitagliptin—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000298	0.0012	CcSEcCtD
Sitagliptin—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000298	0.0012	CcSEcCtD
Sitagliptin—Urticaria—Etoposide—urinary bladder cancer	0.000297	0.0012	CcSEcCtD
Sitagliptin—Abdominal pain—Etoposide—urinary bladder cancer	0.000296	0.00119	CcSEcCtD
Sitagliptin—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000296	0.00119	CcSEcCtD
Sitagliptin—CYP2C8—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000296	0.0049	CbGpPWpGaD
Sitagliptin—Eye disorder—Methotrexate—urinary bladder cancer	0.000295	0.00119	CcSEcCtD
Sitagliptin—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000295	0.00119	CcSEcCtD
Sitagliptin—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000294	0.00118	CcSEcCtD
Sitagliptin—Asthenia—Cisplatin—urinary bladder cancer	0.000293	0.00118	CcSEcCtD
Sitagliptin—Pharyngitis—Epirubicin—urinary bladder cancer	0.000293	0.00118	CcSEcCtD
Sitagliptin—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000293	0.00118	CcSEcCtD
Sitagliptin—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000292	0.00118	CcSEcCtD
Sitagliptin—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000291	0.00117	CcSEcCtD
Sitagliptin—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.00029	0.00117	CcSEcCtD
Sitagliptin—Urethral disorder—Epirubicin—urinary bladder cancer	0.000289	0.00117	CcSEcCtD
Sitagliptin—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000288	0.00116	CcSEcCtD
Sitagliptin—Angiopathy—Methotrexate—urinary bladder cancer	0.000286	0.00115	CcSEcCtD
Sitagliptin—Sinusitis—Doxorubicin—urinary bladder cancer	0.000285	0.00115	CcSEcCtD
Sitagliptin—Immune system disorder—Methotrexate—urinary bladder cancer	0.000285	0.00115	CcSEcCtD
Sitagliptin—Dizziness—Fluorouracil—urinary bladder cancer	0.000285	0.00115	CcSEcCtD
Sitagliptin—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000284	0.00115	CcSEcCtD
Sitagliptin—Diarrhoea—Cisplatin—urinary bladder cancer	0.000279	0.00113	CcSEcCtD
Sitagliptin—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000279	0.00113	CcSEcCtD
Sitagliptin—Vomiting—Gemcitabine—urinary bladder cancer	0.000279	0.00112	CcSEcCtD
Sitagliptin—Mental disorder—Methotrexate—urinary bladder cancer	0.000276	0.00111	CcSEcCtD
Sitagliptin—Rash—Gemcitabine—urinary bladder cancer	0.000276	0.00111	CcSEcCtD
Sitagliptin—Dermatitis—Gemcitabine—urinary bladder cancer	0.000276	0.00111	CcSEcCtD
Sitagliptin—Eye disorder—Epirubicin—urinary bladder cancer	0.000276	0.00111	CcSEcCtD
Sitagliptin—Hypersensitivity—Etoposide—urinary bladder cancer	0.000276	0.00111	CcSEcCtD
Sitagliptin—Malnutrition—Methotrexate—urinary bladder cancer	0.000275	0.00111	CcSEcCtD
Sitagliptin—Headache—Gemcitabine—urinary bladder cancer	0.000274	0.00111	CcSEcCtD
Sitagliptin—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000274	0.0011	CcSEcCtD
Sitagliptin—Vomiting—Fluorouracil—urinary bladder cancer	0.000274	0.0011	CcSEcCtD
Sitagliptin—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000272	0.0011	CcSEcCtD
Sitagliptin—Rash—Fluorouracil—urinary bladder cancer	0.000272	0.0011	CcSEcCtD
Sitagliptin—Dermatitis—Fluorouracil—urinary bladder cancer	0.000271	0.00109	CcSEcCtD
Sitagliptin—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000271	0.00109	CcSEcCtD
Sitagliptin—Headache—Fluorouracil—urinary bladder cancer	0.00027	0.00109	CcSEcCtD
Sitagliptin—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.00027	0.00109	CcSEcCtD
Sitagliptin—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000269	0.00109	CcSEcCtD
Sitagliptin—Asthenia—Etoposide—urinary bladder cancer	0.000268	0.00108	CcSEcCtD
Sitagliptin—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000268	0.00108	CcSEcCtD
Sitagliptin—Angiopathy—Epirubicin—urinary bladder cancer	0.000268	0.00108	CcSEcCtD
Sitagliptin—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000268	0.00108	CcSEcCtD
Sitagliptin—Immune system disorder—Epirubicin—urinary bladder cancer	0.000267	0.00108	CcSEcCtD
Sitagliptin—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000266	0.00107	CcSEcCtD
Sitagliptin—Back pain—Methotrexate—urinary bladder cancer	0.000266	0.00107	CcSEcCtD
Sitagliptin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000262	0.00435	CbGpPWpGaD
Sitagliptin—Nausea—Gemcitabine—urinary bladder cancer	0.00026	0.00105	CcSEcCtD
Sitagliptin—Vomiting—Cisplatin—urinary bladder cancer	0.00026	0.00105	CcSEcCtD
Sitagliptin—Vision blurred—Methotrexate—urinary bladder cancer	0.000259	0.00104	CcSEcCtD
Sitagliptin—Mental disorder—Epirubicin—urinary bladder cancer	0.000259	0.00104	CcSEcCtD
Sitagliptin—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000258	0.00104	CcSEcCtD
Sitagliptin—Rash—Cisplatin—urinary bladder cancer	0.000257	0.00104	CcSEcCtD
Sitagliptin—Dermatitis—Cisplatin—urinary bladder cancer	0.000257	0.00104	CcSEcCtD
Sitagliptin—Malnutrition—Epirubicin—urinary bladder cancer	0.000257	0.00104	CcSEcCtD
Sitagliptin—Diarrhoea—Etoposide—urinary bladder cancer	0.000256	0.00103	CcSEcCtD
Sitagliptin—Nausea—Fluorouracil—urinary bladder cancer	0.000256	0.00103	CcSEcCtD
Sitagliptin—Eye disorder—Doxorubicin—urinary bladder cancer	0.000255	0.00103	CcSEcCtD
Sitagliptin—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000255	0.00103	CcSEcCtD
Sitagliptin—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000253	0.00102	CcSEcCtD
Sitagliptin—Flatulence—Epirubicin—urinary bladder cancer	0.000253	0.00102	CcSEcCtD
Sitagliptin—Tension—Epirubicin—urinary bladder cancer	0.000252	0.00102	CcSEcCtD
Sitagliptin—Nervousness—Epirubicin—urinary bladder cancer	0.00025	0.00101	CcSEcCtD
Sitagliptin—Back pain—Epirubicin—urinary bladder cancer	0.000249	0.001	CcSEcCtD
Sitagliptin—Angiopathy—Doxorubicin—urinary bladder cancer	0.000248	0.000999	CcSEcCtD
Sitagliptin—Malaise—Methotrexate—urinary bladder cancer	0.000248	0.000999	CcSEcCtD
Sitagliptin—Dizziness—Etoposide—urinary bladder cancer	0.000247	0.000998	CcSEcCtD
Sitagliptin—Muscle spasms—Epirubicin—urinary bladder cancer	0.000247	0.000996	CcSEcCtD
Sitagliptin—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000247	0.000995	CcSEcCtD
Sitagliptin—Vertigo—Methotrexate—urinary bladder cancer	0.000247	0.000995	CcSEcCtD
Sitagliptin—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000246	0.000993	CcSEcCtD
Sitagliptin—Nausea—Cisplatin—urinary bladder cancer	0.000243	0.000978	CcSEcCtD
Sitagliptin—Vision blurred—Epirubicin—urinary bladder cancer	0.000242	0.000977	CcSEcCtD
Sitagliptin—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.00024	0.00399	CbGpPWpGaD
Sitagliptin—Cough—Methotrexate—urinary bladder cancer	0.00024	0.000966	CcSEcCtD
Sitagliptin—Mental disorder—Doxorubicin—urinary bladder cancer	0.000239	0.000965	CcSEcCtD
Sitagliptin—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000238	0.000962	CcSEcCtD
Sitagliptin—Vomiting—Etoposide—urinary bladder cancer	0.000238	0.000959	CcSEcCtD
Sitagliptin—Malnutrition—Doxorubicin—urinary bladder cancer	0.000238	0.000959	CcSEcCtD
Sitagliptin—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000237	0.00393	CbGpPWpGaD
Sitagliptin—Rash—Etoposide—urinary bladder cancer	0.000236	0.000951	CcSEcCtD
Sitagliptin—Dermatitis—Etoposide—urinary bladder cancer	0.000236	0.00095	CcSEcCtD
Sitagliptin—Headache—Etoposide—urinary bladder cancer	0.000234	0.000945	CcSEcCtD
Sitagliptin—Flatulence—Doxorubicin—urinary bladder cancer	0.000234	0.000945	CcSEcCtD
Sitagliptin—Arthralgia—Methotrexate—urinary bladder cancer	0.000234	0.000943	CcSEcCtD
Sitagliptin—Myalgia—Methotrexate—urinary bladder cancer	0.000234	0.000943	CcSEcCtD
Sitagliptin—Tension—Doxorubicin—urinary bladder cancer	0.000233	0.000941	CcSEcCtD
Sitagliptin—CYP2C8—Biological oxidations—NAT2—urinary bladder cancer	0.000233	0.00386	CbGpPWpGaD
Sitagliptin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000232	0.000936	CcSEcCtD
Sitagliptin—Malaise—Epirubicin—urinary bladder cancer	0.000232	0.000935	CcSEcCtD
Sitagliptin—Discomfort—Methotrexate—urinary bladder cancer	0.000231	0.000931	CcSEcCtD
Sitagliptin—Nervousness—Doxorubicin—urinary bladder cancer	0.000231	0.000931	CcSEcCtD
Sitagliptin—Vertigo—Epirubicin—urinary bladder cancer	0.000231	0.000931	CcSEcCtD
Sitagliptin—Back pain—Doxorubicin—urinary bladder cancer	0.00023	0.000928	CcSEcCtD
Sitagliptin—CYP2C8—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000229	0.00381	CbGpPWpGaD
Sitagliptin—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000229	0.000922	CcSEcCtD
Sitagliptin—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000228	0.00378	CbGpPWpGaD
Sitagliptin—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000228	0.00378	CbGpPWpGaD
Sitagliptin—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000225	0.00373	CbGpPWpGaD
Sitagliptin—Cough—Epirubicin—urinary bladder cancer	0.000224	0.000904	CcSEcCtD
Sitagliptin—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000224	0.000904	CcSEcCtD
Sitagliptin—Vision blurred—Doxorubicin—urinary bladder cancer	0.000224	0.000904	CcSEcCtD
Sitagliptin—Infection—Methotrexate—urinary bladder cancer	0.000223	0.000898	CcSEcCtD
Sitagliptin—Nausea—Etoposide—urinary bladder cancer	0.000222	0.000896	CcSEcCtD
Sitagliptin—Hypertension—Epirubicin—urinary bladder cancer	0.000222	0.000895	CcSEcCtD
Sitagliptin—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000221	0.00089	CcSEcCtD
Sitagliptin—Nervous system disorder—Methotrexate—urinary bladder cancer	0.00022	0.000886	CcSEcCtD
Sitagliptin—Arthralgia—Epirubicin—urinary bladder cancer	0.000219	0.000882	CcSEcCtD
Sitagliptin—Myalgia—Epirubicin—urinary bladder cancer	0.000219	0.000882	CcSEcCtD
Sitagliptin—Anxiety—Epirubicin—urinary bladder cancer	0.000218	0.000879	CcSEcCtD
Sitagliptin—Skin disorder—Methotrexate—urinary bladder cancer	0.000218	0.000878	CcSEcCtD
Sitagliptin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000217	0.000876	CcSEcCtD
Sitagliptin—Discomfort—Epirubicin—urinary bladder cancer	0.000216	0.000872	CcSEcCtD
Sitagliptin—Malaise—Doxorubicin—urinary bladder cancer	0.000214	0.000865	CcSEcCtD
Sitagliptin—Dry mouth—Epirubicin—urinary bladder cancer	0.000214	0.000863	CcSEcCtD
Sitagliptin—Vertigo—Doxorubicin—urinary bladder cancer	0.000214	0.000862	CcSEcCtD
Sitagliptin—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.00021	0.000846	CcSEcCtD
Sitagliptin—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000208	0.00346	CbGpPWpGaD
Sitagliptin—Infection—Epirubicin—urinary bladder cancer	0.000208	0.00084	CcSEcCtD
Sitagliptin—Cough—Doxorubicin—urinary bladder cancer	0.000207	0.000837	CcSEcCtD
Sitagliptin—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000206	0.000829	CcSEcCtD
Sitagliptin—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000206	0.00341	CbGpPWpGaD
Sitagliptin—Hypertension—Doxorubicin—urinary bladder cancer	0.000205	0.000828	CcSEcCtD
Sitagliptin—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000204	0.000823	CcSEcCtD
Sitagliptin—Skin disorder—Epirubicin—urinary bladder cancer	0.000204	0.000822	CcSEcCtD
Sitagliptin—Insomnia—Methotrexate—urinary bladder cancer	0.000203	0.000817	CcSEcCtD
Sitagliptin—Arthralgia—Doxorubicin—urinary bladder cancer	0.000202	0.000816	CcSEcCtD
Sitagliptin—Myalgia—Doxorubicin—urinary bladder cancer	0.000202	0.000816	CcSEcCtD
Sitagliptin—Anxiety—Doxorubicin—urinary bladder cancer	0.000202	0.000814	CcSEcCtD
Sitagliptin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000201	0.000811	CcSEcCtD
Sitagliptin—Discomfort—Doxorubicin—urinary bladder cancer	0.0002	0.000807	CcSEcCtD
Sitagliptin—Somnolence—Methotrexate—urinary bladder cancer	0.000199	0.000803	CcSEcCtD
Sitagliptin—Dry mouth—Doxorubicin—urinary bladder cancer	0.000198	0.000798	CcSEcCtD
Sitagliptin—Dyspepsia—Methotrexate—urinary bladder cancer	0.000197	0.000796	CcSEcCtD
Sitagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.000195	0.00324	CbGpPWpGaD
Sitagliptin—Decreased appetite—Methotrexate—urinary bladder cancer	0.000195	0.000786	CcSEcCtD
Sitagliptin—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000194	0.000783	CcSEcCtD
Sitagliptin—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000193	0.00078	CcSEcCtD
Sitagliptin—Fatigue—Methotrexate—urinary bladder cancer	0.000193	0.000779	CcSEcCtD
Sitagliptin—Infection—Doxorubicin—urinary bladder cancer	0.000193	0.000777	CcSEcCtD
Sitagliptin—Pain—Methotrexate—urinary bladder cancer	0.000192	0.000773	CcSEcCtD
Sitagliptin—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000191	0.000771	CcSEcCtD
Sitagliptin—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.00019	0.000767	CcSEcCtD
Sitagliptin—ABCB1—HIF-1-alpha transcription factor network—TERT—urinary bladder cancer	0.00019	0.00315	CbGpPWpGaD
Sitagliptin—Insomnia—Epirubicin—urinary bladder cancer	0.00019	0.000765	CcSEcCtD
Sitagliptin—Skin disorder—Doxorubicin—urinary bladder cancer	0.000188	0.00076	CcSEcCtD
Sitagliptin—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000188	0.00311	CbGpPWpGaD
Sitagliptin—Somnolence—Epirubicin—urinary bladder cancer	0.000186	0.000752	CcSEcCtD
Sitagliptin—CYP2C8—Biological oxidations—HPGDS—urinary bladder cancer	0.000186	0.00308	CbGpPWpGaD
Sitagliptin—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000185	0.00307	CbGpPWpGaD
Sitagliptin—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000185	0.000745	CcSEcCtD
Sitagliptin—Dyspepsia—Epirubicin—urinary bladder cancer	0.000185	0.000745	CcSEcCtD
Sitagliptin—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000183	0.000739	CcSEcCtD
Sitagliptin—Decreased appetite—Epirubicin—urinary bladder cancer	0.000182	0.000735	CcSEcCtD
Sitagliptin—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000181	0.00073	CcSEcCtD
Sitagliptin—Fatigue—Epirubicin—urinary bladder cancer	0.000181	0.000729	CcSEcCtD
Sitagliptin—CYP2C8—Biological oxidations—GSTT1—urinary bladder cancer	0.00018	0.00299	CbGpPWpGaD
Sitagliptin—Pain—Epirubicin—urinary bladder cancer	0.000179	0.000723	CcSEcCtD
Sitagliptin—Constipation—Epirubicin—urinary bladder cancer	0.000179	0.000723	CcSEcCtD
Sitagliptin—Urticaria—Methotrexate—urinary bladder cancer	0.000178	0.000718	CcSEcCtD
Sitagliptin—Abdominal pain—Methotrexate—urinary bladder cancer	0.000177	0.000714	CcSEcCtD
Sitagliptin—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000177	0.000713	CcSEcCtD
Sitagliptin—Insomnia—Doxorubicin—urinary bladder cancer	0.000176	0.000708	CcSEcCtD
Sitagliptin—CYP2C8—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000174	0.00289	CbGpPWpGaD
Sitagliptin—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000173	0.000697	CcSEcCtD
Sitagliptin—Somnolence—Doxorubicin—urinary bladder cancer	0.000173	0.000696	CcSEcCtD
Sitagliptin—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000171	0.000692	CcSEcCtD
Sitagliptin—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000171	0.000689	CcSEcCtD
Sitagliptin—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000169	0.00068	CcSEcCtD
Sitagliptin—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000168	0.000676	CcSEcCtD
Sitagliptin—Fatigue—Doxorubicin—urinary bladder cancer	0.000167	0.000675	CcSEcCtD
Sitagliptin—ABCB1—Allograft Rejection—FAS—urinary bladder cancer	0.000167	0.00277	CbGpPWpGaD
Sitagliptin—Urticaria—Epirubicin—urinary bladder cancer	0.000167	0.000672	CcSEcCtD
Sitagliptin—Constipation—Doxorubicin—urinary bladder cancer	0.000166	0.000669	CcSEcCtD
Sitagliptin—Pain—Doxorubicin—urinary bladder cancer	0.000166	0.000669	CcSEcCtD
Sitagliptin—Abdominal pain—Epirubicin—urinary bladder cancer	0.000166	0.000669	CcSEcCtD
Sitagliptin—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000165	0.000666	CcSEcCtD
Sitagliptin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000162	0.00268	CbGpPWpGaD
Sitagliptin—Asthenia—Methotrexate—urinary bladder cancer	0.000161	0.000648	CcSEcCtD
Sitagliptin—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.00016	0.000645	CcSEcCtD
Sitagliptin—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000159	0.00064	CcSEcCtD
Sitagliptin—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000155	0.000623	CcSEcCtD
Sitagliptin—Urticaria—Doxorubicin—urinary bladder cancer	0.000154	0.000622	CcSEcCtD
Sitagliptin—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000153	0.000619	CcSEcCtD
Sitagliptin—Diarrhoea—Methotrexate—urinary bladder cancer	0.000153	0.000618	CcSEcCtD
Sitagliptin—Asthenia—Epirubicin—urinary bladder cancer	0.00015	0.000607	CcSEcCtD
Sitagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.000149	0.00247	CbGpPWpGaD
Sitagliptin—ABCB1—HIF-1-alpha transcription factor network—CREBBP—urinary bladder cancer	0.000148	0.00246	CbGpPWpGaD
Sitagliptin—Dizziness—Methotrexate—urinary bladder cancer	0.000148	0.000598	CcSEcCtD
Sitagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000148	0.00246	CbGpPWpGaD
Sitagliptin—Diarrhoea—Epirubicin—urinary bladder cancer	0.000143	0.000579	CcSEcCtD
Sitagliptin—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000143	0.000577	CcSEcCtD
Sitagliptin—Vomiting—Methotrexate—urinary bladder cancer	0.000142	0.000575	CcSEcCtD
Sitagliptin—Rash—Methotrexate—urinary bladder cancer	0.000141	0.00057	CcSEcCtD
Sitagliptin—Dermatitis—Methotrexate—urinary bladder cancer	0.000141	0.000569	CcSEcCtD
Sitagliptin—Headache—Methotrexate—urinary bladder cancer	0.00014	0.000566	CcSEcCtD
Sitagliptin—Asthenia—Doxorubicin—urinary bladder cancer	0.000139	0.000561	CcSEcCtD
Sitagliptin—Dizziness—Epirubicin—urinary bladder cancer	0.000139	0.000559	CcSEcCtD
Sitagliptin—DPP4—Metabolism of proteins—IGF1—urinary bladder cancer	0.000136	0.00225	CbGpPWpGaD
Sitagliptin—ABCB1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000135	0.00224	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000134	0.00223	CbGpPWpGaD
Sitagliptin—Vomiting—Epirubicin—urinary bladder cancer	0.000133	0.000538	CcSEcCtD
Sitagliptin—Nausea—Methotrexate—urinary bladder cancer	0.000133	0.000537	CcSEcCtD
Sitagliptin—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000133	0.000535	CcSEcCtD
Sitagliptin—Rash—Epirubicin—urinary bladder cancer	0.000132	0.000533	CcSEcCtD
Sitagliptin—Dermatitis—Epirubicin—urinary bladder cancer	0.000132	0.000533	CcSEcCtD
Sitagliptin—Headache—Epirubicin—urinary bladder cancer	0.000131	0.00053	CcSEcCtD
Sitagliptin—Dizziness—Doxorubicin—urinary bladder cancer	0.000128	0.000518	CcSEcCtD
Sitagliptin—CYP2C8—Biological oxidations—GSTP1—urinary bladder cancer	0.000125	0.00207	CbGpPWpGaD
Sitagliptin—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000125	0.00207	CbGpPWpGaD
Sitagliptin—Nausea—Epirubicin—urinary bladder cancer	0.000125	0.000502	CcSEcCtD
Sitagliptin—Vomiting—Doxorubicin—urinary bladder cancer	0.000123	0.000498	CcSEcCtD
Sitagliptin—CYP2C8—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000123	0.00205	CbGpPWpGaD
Sitagliptin—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000123	0.00204	CbGpPWpGaD
Sitagliptin—Rash—Doxorubicin—urinary bladder cancer	0.000122	0.000493	CcSEcCtD
Sitagliptin—Dermatitis—Doxorubicin—urinary bladder cancer	0.000122	0.000493	CcSEcCtD
Sitagliptin—Headache—Doxorubicin—urinary bladder cancer	0.000122	0.00049	CcSEcCtD
Sitagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.000119	0.00198	CbGpPWpGaD
Sitagliptin—Nausea—Doxorubicin—urinary bladder cancer	0.000115	0.000465	CcSEcCtD
Sitagliptin—CYP2C8—Biological oxidations—GSTM1—urinary bladder cancer	0.000115	0.00191	CbGpPWpGaD
Sitagliptin—CYP2C8—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000113	0.00188	CbGpPWpGaD
Sitagliptin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	0.000112	0.00185	CbGpPWpGaD
Sitagliptin—DPP4—Metabolism of proteins—CXCL8—urinary bladder cancer	0.000109	0.00181	CbGpPWpGaD
Sitagliptin—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	0.000102	0.00169	CbGpPWpGaD
Sitagliptin—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	0.000101	0.00168	CbGpPWpGaD
Sitagliptin—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	9.98e-05	0.00166	CbGpPWpGaD
Sitagliptin—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	9.77e-05	0.00162	CbGpPWpGaD
Sitagliptin—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	9.75e-05	0.00162	CbGpPWpGaD
Sitagliptin—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	9.68e-05	0.00161	CbGpPWpGaD
Sitagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	9.48e-05	0.00157	CbGpPWpGaD
Sitagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	9.31e-05	0.00154	CbGpPWpGaD
Sitagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	8.25e-05	0.00137	CbGpPWpGaD
Sitagliptin—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	7.96e-05	0.00132	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism—GSTZ1—urinary bladder cancer	7.66e-05	0.00127	CbGpPWpGaD
Sitagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	7.29e-05	0.00121	CbGpPWpGaD
Sitagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	7.26e-05	0.0012	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism—GSTO2—urinary bladder cancer	7.26e-05	0.0012	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism—NAT1—urinary bladder cancer	7.26e-05	0.0012	CbGpPWpGaD
Sitagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	7.23e-05	0.0012	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	7.14e-05	0.00118	CbGpPWpGaD
Sitagliptin—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	7.1e-05	0.00118	CbGpPWpGaD
Sitagliptin—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	6.71e-05	0.00111	CbGpPWpGaD
Sitagliptin—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	6.67e-05	0.00111	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism—UGT2B7—urinary bladder cancer	6.64e-05	0.0011	CbGpPWpGaD
Sitagliptin—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	6.62e-05	0.0011	CbGpPWpGaD
Sitagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	6.34e-05	0.00105	CbGpPWpGaD
Sitagliptin—ABCB1—Metabolism—GSTO2—urinary bladder cancer	6.33e-05	0.00105	CbGpPWpGaD
Sitagliptin—ABCB1—Metabolism—NAT1—urinary bladder cancer	6.33e-05	0.00105	CbGpPWpGaD
Sitagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	6.26e-05	0.00104	CbGpPWpGaD
Sitagliptin—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	6.17e-05	0.00102	CbGpPWpGaD
Sitagliptin—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	6.08e-05	0.00101	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism—CYP4B1—urinary bladder cancer	5.98e-05	0.000992	CbGpPWpGaD
Sitagliptin—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	5.79e-05	0.00096	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism—SLC19A1—urinary bladder cancer	5.65e-05	0.000937	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism—PRSS3—urinary bladder cancer	5.5e-05	0.000913	CbGpPWpGaD
Sitagliptin—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	5.38e-05	0.000892	CbGpPWpGaD
Sitagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	5.31e-05	0.00088	CbGpPWpGaD
Sitagliptin—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	5.21e-05	0.000864	CbGpPWpGaD
Sitagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	5.19e-05	0.000861	CbGpPWpGaD
Sitagliptin—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	4.92e-05	0.000816	CbGpPWpGaD
Sitagliptin—ABCB1—Metabolism—PRSS3—urinary bladder cancer	4.79e-05	0.000795	CbGpPWpGaD
Sitagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	4.69e-05	0.000778	CbGpPWpGaD
Sitagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	4.54e-05	0.000752	CbGpPWpGaD
Sitagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	4.53e-05	0.000751	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.41e-05	0.000732	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism—TYMP—urinary bladder cancer	4.4e-05	0.00073	CbGpPWpGaD
Sitagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	4.32e-05	0.000716	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.23e-05	0.000701	CbGpPWpGaD
Sitagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	4.2e-05	0.000696	CbGpPWpGaD
Sitagliptin—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	4.11e-05	0.000682	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism—NAT2—urinary bladder cancer	3.98e-05	0.00066	CbGpPWpGaD
Sitagliptin—CYP3A4—Metabolism—NAT1—urinary bladder cancer	3.9e-05	0.000646	CbGpPWpGaD
Sitagliptin—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	3.9e-05	0.000646	CbGpPWpGaD
Sitagliptin—ABCB1—Metabolism—TYMP—urinary bladder cancer	3.83e-05	0.000636	CbGpPWpGaD
Sitagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	3.76e-05	0.000624	CbGpPWpGaD
Sitagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	3.68e-05	0.00061	CbGpPWpGaD
Sitagliptin—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	3.56e-05	0.000591	CbGpPWpGaD
Sitagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	3.5e-05	0.000581	CbGpPWpGaD
Sitagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	3.48e-05	0.000576	CbGpPWpGaD
Sitagliptin—ABCB1—Metabolism—NAT2—urinary bladder cancer	3.47e-05	0.000575	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism—RRM2—urinary bladder cancer	3.43e-05	0.00057	CbGpPWpGaD
Sitagliptin—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	3.21e-05	0.000532	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	3.18e-05	0.000528	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism—ENO2—urinary bladder cancer	3.18e-05	0.000528	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.16e-05	0.000524	CbGpPWpGaD
Sitagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	3.09e-05	0.000512	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	3.09e-05	0.000512	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.04e-05	0.000504	CbGpPWpGaD
Sitagliptin—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	3.03e-05	0.000503	CbGpPWpGaD
Sitagliptin—ABCB1—Metabolism—RRM2—urinary bladder cancer	2.99e-05	0.000496	CbGpPWpGaD
Sitagliptin—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	2.95e-05	0.00049	CbGpPWpGaD
Sitagliptin—ABCB1—Metabolism—HPGDS—urinary bladder cancer	2.77e-05	0.00046	CbGpPWpGaD
Sitagliptin—ABCB1—Metabolism—ENO2—urinary bladder cancer	2.77e-05	0.00046	CbGpPWpGaD
Sitagliptin—ABCB1—Metabolism—GSTT1—urinary bladder cancer	2.69e-05	0.000446	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism—NQO1—urinary bladder cancer	2.56e-05	0.000425	CbGpPWpGaD
Sitagliptin—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.52e-05	0.000417	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.49e-05	0.000413	CbGpPWpGaD
Sitagliptin—CYP3A4—Metabolism—TYMP—urinary bladder cancer	2.36e-05	0.000392	CbGpPWpGaD
Sitagliptin—ABCB1—Metabolism—NQO1—urinary bladder cancer	2.23e-05	0.00037	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.17e-05	0.00036	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	2.14e-05	0.000355	CbGpPWpGaD
Sitagliptin—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.14e-05	0.000354	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.07e-05	0.000343	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism—TYMS—urinary bladder cancer	1.99e-05	0.00033	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	1.97e-05	0.000326	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	1.97e-05	0.000326	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism—GPX1—urinary bladder cancer	1.88e-05	0.000312	CbGpPWpGaD
Sitagliptin—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.86e-05	0.000309	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	1.85e-05	0.000306	CbGpPWpGaD
Sitagliptin—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.84e-05	0.000306	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	1.74e-05	0.000288	CbGpPWpGaD
Sitagliptin—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.73e-05	0.000287	CbGpPWpGaD
Sitagliptin—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.71e-05	0.000284	CbGpPWpGaD
Sitagliptin—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.71e-05	0.000284	CbGpPWpGaD
Sitagliptin—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.71e-05	0.000283	CbGpPWpGaD
Sitagliptin—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.71e-05	0.000283	CbGpPWpGaD
Sitagliptin—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.66e-05	0.000275	CbGpPWpGaD
Sitagliptin—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.64e-05	0.000272	CbGpPWpGaD
Sitagliptin—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.61e-05	0.000267	CbGpPWpGaD
Sitagliptin—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.51e-05	0.000251	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism—PPARG—urinary bladder cancer	1.41e-05	0.000234	CbGpPWpGaD
Sitagliptin—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.38e-05	0.000228	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	1.35e-05	0.000224	CbGpPWpGaD
Sitagliptin—ABCB1—Metabolism—PPARG—urinary bladder cancer	1.23e-05	0.000203	CbGpPWpGaD
Sitagliptin—ABCB1—Metabolism—CREBBP—urinary bladder cancer	1.18e-05	0.000195	CbGpPWpGaD
Sitagliptin—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.15e-05	0.00019	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	1.11e-05	0.000184	CbGpPWpGaD
Sitagliptin—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.07e-05	0.000177	CbGpPWpGaD
Sitagliptin—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.05e-05	0.000175	CbGpPWpGaD
Sitagliptin—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.05e-05	0.000175	CbGpPWpGaD
Sitagliptin—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.01e-05	0.000168	CbGpPWpGaD
Sitagliptin—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	9.92e-06	0.000164	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism—PTEN—urinary bladder cancer	9.66e-06	0.00016	CbGpPWpGaD
Sitagliptin—ABCB1—Metabolism—PTGS2—urinary bladder cancer	9.65e-06	0.00016	CbGpPWpGaD
Sitagliptin—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	9.32e-06	0.000155	CbGpPWpGaD
Sitagliptin—CYP2C8—Metabolism—EP300—urinary bladder cancer	9.21e-06	0.000153	CbGpPWpGaD
Sitagliptin—ABCB1—Metabolism—PTEN—urinary bladder cancer	8.42e-06	0.00014	CbGpPWpGaD
Sitagliptin—ABCB1—Metabolism—EP300—urinary bladder cancer	8.03e-06	0.000133	CbGpPWpGaD
Sitagliptin—CYP3A4—Metabolism—PPARG—urinary bladder cancer	7.56e-06	0.000125	CbGpPWpGaD
Sitagliptin—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	7.26e-06	0.00012	CbGpPWpGaD
Sitagliptin—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	5.95e-06	9.86e-05	CbGpPWpGaD
Sitagliptin—CYP3A4—Metabolism—PTEN—urinary bladder cancer	5.19e-06	8.6e-05	CbGpPWpGaD
Sitagliptin—CYP3A4—Metabolism—EP300—urinary bladder cancer	4.95e-06	8.2e-05	CbGpPWpGaD
